Business
Ventripoint Announces Sponsorship of the 55th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
(TheNewswire) Toronto, Ontario – TheNewswire – May 17 2022 ...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Announces Sponsorship of the 55th Annual Meeting of the Association for European Paediatric and Congenital Cardiology\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Toronto, Ontario – TheNewswire –\nMay 17 2022\n \n \n - Ventripoint Diagnostics Ltd.\n(\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"), (TSXV:VPT\n \n \n )\n \n \n ;\n \n \n (\n \n \n OTC:VPTDF) is pleased to announce that it will be a sponsor\nfor the 55th Annual Meeting of the Association for European Paediatric\nand Congenital Cardiology (AEPC). The AEPC is a network of specialists\nin the paediatric and congenital cardiology field who strive to\npromote the sharing of information and resources within the community.\nThe AEPC is currently one of the largest global associations in the\ncardiac field with over 1,000 paediatric cardiologists.\n \n \n \n \n The conference will be held on May 25-28, 2022, in\nGeneva, Switzerland and is hosted by the local organizing committee\nfrom the “Centre Universitaire de Cardiologie et Chirurgie Cardiaque\nPédiatrique” a collaboration between the University Hospitals of\nGeneva (HUG) and Vaudois University Hospital Center (CHUV) in\nLausanne. The conference will focus on the latest advancements in the\nresearch and treatment of paediatric and congenital cardiology.\nPresentation topics will include arrhythmia/electrophysiology and\nbasic science, genetics, COVID-19, surgery and preventative care, and\nmany more engaging topics. As a sponsor at the event, Ventripoint’s\nVMS+ system will be highlighted in various presentations and in the\nexhibition space. This meeting presents Ventripoint with an excellent\nopportunity to engage with\n \n \n the global congenital\ncardiologist community.\n \n \n \n \n About Ventripoint Diagnostics\nLtd.\n \n \n \n \n Ventripoint\n \n \n has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary KBR technology, which is the result of a decade of\ndevelopment and provides accurate volumetric cardiac measurements\nequivalent to MRI. This affordable, gold-standard alternative allows\ncardiologists greater confidence in the management of their patients.\nProviding better care to patients serves as a springboard and basic\nst...